• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

分子靶向治疗药物在乳腺癌治疗中的作用:一篇综述文章

Role of Molecular Targeted Therapeutic Drugs in Treatment of Breast Cancer: A Review Article.

作者信息

Singh Himanshu

机构信息

Department of Oral and Maxillofacial Pathology and Oral Microbiology, Index Institute of Dental Sciences, Indore, Madhya Pradesh, India.

出版信息

Glob Med Genet. 2023 May 23;10(2):79-86. doi: 10.1055/s-0043-57247. eCollection 2023 Jun.

DOI:10.1055/s-0043-57247
PMID:37228871
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10205396/
Abstract

Breast cancer is a multifactor, multistage, and heterogeneous disease. Systemic treatment of breast cancer has changed significantly over the last decade. With a better knowledge of the pathogenesis, researchers and scientists have discovered numerous signaling pathways and synonymous therapeutic targets in breast cancer. Because of the molecular nature of breast cancer, which makes it difficult to understand, previous attempts to treat or prevent it have failed. However, recent decades have provided effective therapeutic targets for treatment. In this review, literature or information on various targeted therapy for breast cancer is discussed. English language articles were explored in numerous directory or databases like PubMed, Web of Sciences, Google Scholar, ScienceDirect, and Scopus. The important keywords used for searching databases are "Breast cancer," "Targeted therapy in breast cancer," "Therapeutic drugs in breast cancer," and "Molecular targets in breast cancer."

摘要

乳腺癌是一种多因素、多阶段且异质性的疾病。在过去十年中,乳腺癌的全身治疗发生了显著变化。随着对发病机制的深入了解,研究人员和科学家们在乳腺癌中发现了众多信号通路和相应的治疗靶点。由于乳腺癌的分子特性使其难以理解,以往治疗或预防乳腺癌的尝试均告失败。然而,近几十年来已为治疗提供了有效的治疗靶点。在本综述中,将讨论有关乳腺癌各种靶向治疗的文献或信息。通过在众多数据库或索引中检索英文文章,如PubMed、科学网、谷歌学术、ScienceDirect和Scopus。用于搜索数据库的重要关键词为“乳腺癌”、“乳腺癌的靶向治疗”、“乳腺癌的治疗药物”以及“乳腺癌的分子靶点”。

相似文献

1
Role of Molecular Targeted Therapeutic Drugs in Treatment of Breast Cancer: A Review Article.分子靶向治疗药物在乳腺癌治疗中的作用:一篇综述文章
Glob Med Genet. 2023 May 23;10(2):79-86. doi: 10.1055/s-0043-57247. eCollection 2023 Jun.
2
Role of Molecular Targeted Therapeutic Drugs in Treatment of Glioblastoma: A Review Article.分子靶向治疗药物在胶质母细胞瘤治疗中的作用:一篇综述文章。
Glob Med Genet. 2023 Apr 17;10(2):42-47. doi: 10.1055/s-0043-57028. eCollection 2023 Jun.
3
Role of Molecular Targeted Therapeutic Drugs in Treatment of Oral Squamous Cell Carcinoma: Development and Current Strategies-A Review Article.分子靶向治疗药物在口腔鳞状细胞癌治疗中的作用:进展与当前策略——一篇综述文章
Glob Med Genet. 2022 Sep 19;9(3):242-246. doi: 10.1055/s-0042-1756663. eCollection 2022 Sep.
4
Novel Therapeutics Against Breast Cancer Stem Cells by Targeting Surface Markers and Signaling Pathways.通过靶向表面标志物和信号通路对抗乳腺癌干细胞的新型疗法
Curr Stem Cell Res Ther. 2019;14(8):669-682. doi: 10.2174/1574888X14666190628104721.
5
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
6
Progress in targeted therapy for breast cancer.乳腺癌靶向治疗的进展
Chronic Dis Transl Med. 2018 Jul 7;4(3):164-175. doi: 10.1016/j.cdtm.2018.04.002. eCollection 2018 Sep.
7
Therapeutic impacts of microRNAs in breast cancer by their roles in regulating processes involved in this disease.微小RNA通过其在调节乳腺癌相关过程中的作用对乳腺癌产生的治疗影响。
J Res Med Sci. 2017 Dec 26;22:130. doi: 10.4103/jrms.JRMS_967_16. eCollection 2017.
8
Advancements in Applications of Surface Modified Nanomaterials for Cancer Theranostics.表面改性纳米材料在癌症诊疗中的应用进展
Curr Drug Metab. 2017;18(11):983-999. doi: 10.2174/1389200218666171002122039.
9
Comparisons of citations in Web of Science, Scopus, and Google Scholar for articles published in general medical journals.对发表在普通医学期刊上的文章在科学网、Scopus和谷歌学术中被引用情况的比较。
JAMA. 2009 Sep 9;302(10):1092-6. doi: 10.1001/jama.2009.1307.
10
Risks and management of hypertension in cancer patients undergoing targeted therapy: a review.接受靶向治疗的癌症患者高血压的风险与管理:综述
Clin Hypertens. 2022 May 15;28(1):14. doi: 10.1186/s40885-022-00197-3.

引用本文的文献

1
The role of environmentally mediated drug resistance in facilitating the spatial distribution of residual disease.环境介导的耐药性在促进残留疾病空间分布中的作用。
Commun Biol. 2025 Aug 9;8(1):1189. doi: 10.1038/s42003-025-08585-9.
2
Evaluation of the efficacy of totally implantable venous access port in breast cancer patients undergoing chemotherapy.完全植入式静脉输液港在乳腺癌化疗患者中的疗效评估
Discov Oncol. 2025 Mar 24;16(1):383. doi: 10.1007/s12672-025-02020-5.
3
Identification of a novel immune checkpoint-related gene signature predicts prognosis and immunotherapy in breast cancer and experiment verification.一种新型免疫检查点相关基因特征的鉴定可预测乳腺癌的预后及免疫治疗效果并进行实验验证。
Sci Rep. 2024 Dec 28;14(1):31065. doi: 10.1038/s41598-024-82266-1.
4
Design and Synthesis of c-Met and HDAC Dual Inhibitors for the Treatment of Breast Cancer.用于治疗乳腺癌的c-Met和HDAC双重抑制剂的设计与合成
ACS Med Chem Lett. 2024 Aug 22;15(9):1516-1525. doi: 10.1021/acsmedchemlett.4c00256. eCollection 2024 Sep 12.
5
The Promise and Challenges of Integrating Biological and Prevention Sciences: A Community-Engaged Model for the Next Generation of Translational Research.整合生物学与预防科学的前景与挑战:一种面向下一代转化研究的社区参与模式
Prev Sci. 2024 Dec;25(8):1177-1199. doi: 10.1007/s11121-024-01720-8. Epub 2024 Sep 3.
6
Crosstalk of methylation and tamoxifen in breast cancer (Review).甲基化与乳腺癌他莫昔芬治疗的相互作用(综述)。
Mol Med Rep. 2024 Oct;30(4). doi: 10.3892/mmr.2024.13304. Epub 2024 Aug 12.
7
Combined Photosensitive Gene Therapy Effective Against Triple-Negative Breast Cancer in Mice Model.联合光敏基因疗法有效治疗小鼠三阴性乳腺癌模型。
Int J Nanomedicine. 2024 Feb 23;19:1809-1825. doi: 10.2147/IJN.S449042. eCollection 2024.

本文引用的文献

1
Treating Advanced Unresectable or Metastatic HER2-Positive Breast Cancer: A Spotlight on Tucatinib.治疗晚期不可切除或转移性HER2阳性乳腺癌:图卡替尼聚焦
Breast Cancer (Dove Med Press). 2021 May 26;13:361-381. doi: 10.2147/BCTT.S268451. eCollection 2021.
2
HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now.人表皮生长因子受体2阳性乳腺癌与酪氨酸激酶抑制剂:时机已至。
NPJ Breast Cancer. 2021 May 20;7(1):56. doi: 10.1038/s41523-021-00265-1.
3
PI3K inhibitors: review and new strategies.PI3K抑制剂:综述与新策略
Chem Sci. 2020 May 19;11(23):5855-5865. doi: 10.1039/d0sc01676d. eCollection 2020 Jun 21.
4
A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer.一项关于pictilisib(GDC-0941)联合紫杉醇,联合或不联合贝伐珠单抗或曲妥珠单抗,以及联合来曲唑治疗晚期乳腺癌的 Ib 期研究。
Breast Cancer Res. 2018 Sep 5;20(1):109. doi: 10.1186/s13058-018-1015-x.
5
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.Buparlisib 联合氟维司群治疗接受 mTOR 抑制剂治疗后进展的激素受体阳性、HER2 阴性晚期乳腺癌的绝经后妇女(BELLE-3):一项随机、双盲、安慰剂对照的 3 期临床试验。
Lancet Oncol. 2018 Jan;19(1):87-100. doi: 10.1016/S1470-2045(17)30688-5. Epub 2017 Dec 7.
6
Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study.依维莫司在中国转移性HR阳性、HER2阴性乳腺癌患者中的疗效与安全性:一项真实世界回顾性研究
Oncotarget. 2017 Mar 17;8(35):59810-59822. doi: 10.18632/oncotarget.16336. eCollection 2017 Aug 29.
7
CDK4/6 inhibition triggers anti-tumour immunity.细胞周期蛋白依赖性激酶4/6(CDK4/6)抑制可触发抗肿瘤免疫。
Nature. 2017 Aug 24;548(7668):471-475. doi: 10.1038/nature23465. Epub 2017 Aug 16.
8
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.在绝经后激素受体阳性、人表皮生长因子受体2阴性的晚期乳腺癌患者中,比较布帕利西布联合氟维司群与安慰剂联合氟维司群的疗效(BELLE-2):一项随机、双盲、安慰剂对照的3期试验。
Lancet Oncol. 2017 Jul;18(7):904-916. doi: 10.1016/S1470-2045(17)30376-5. Epub 2017 May 30.
9
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR/HER2 Metastatic Breast Cancer.MONARCH 1 研究:阿贝西利(一种 CDK4 和 CDK6 抑制剂)单药治疗难治性 HR/HER2 转移性乳腺癌的 II 期研究。
Clin Cancer Res. 2017 Sep 1;23(17):5218-5224. doi: 10.1158/1078-0432.CCR-17-0754. Epub 2017 May 22.
10
Palbociclib and Letrozole in Advanced Breast Cancer.帕博西尼联合来曲唑治疗晚期乳腺癌。
N Engl J Med. 2016 Nov 17;375(20):1925-1936. doi: 10.1056/NEJMoa1607303.